How [18F]-FDG-PET/CT Affects Clinical Management of Patients with Germ Cell Tumors in the Real World

The aim of this study was to evaluate the impact of PET/CT on clinical management of patients with germ cell tumors (GCTs) conducted in a real-world setting, including avoidance of invasive procedures, additional diagnostic imaging, and changes in treatment. Patients with GCTs were prospectively enr...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-07, Vol.15 (14), p.3652
Main Authors: Liang, Cecilia, Sekler, Julia, Gückel, Brigitte, Pfannenberg, Christina, Dittmann, Helmut, Seith, Ferdinand, Amend, Bastian, Nikolaou, Konstantin, Reinert, Christian Philipp
Format: Article
Language:English
Subjects:
Accuracy
Biopsy
Cancer
Care and treatment
Chemotherapy
Clinical medicine
Computed tomography
Diagnosis
Diagnostic tests
Disease management
Germ cell tumors
Invasiveness
Life span
Lymphatic system
Medical imaging
Medical research
Medicine, Experimental
Metastasis
Patients
PET imaging
Positron emission tomography
Questionnaires
Therapeutic applications
Tomography
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to evaluate the impact of PET/CT on clinical management of patients with germ cell tumors (GCTs) conducted in a real-world setting, including avoidance of invasive procedures, additional diagnostic imaging, and changes in treatment. Patients with GCTs were prospectively enrolled into a PET/CT registry study between May 2013 and April 2021. Intended patient management prior and after PET/CT was documented using standardized questionnaires. Changes in oncologic staging and clinical management after PET/CT were recorded, including planned treatment and planned additional diagnostics. Forty-three male patients with GCTs were included consecutively in this study. After PET/CT, oncologic staging changed in 22/43 patients (51%), with upstaging in seven cases (16%), downstaging in ten cases (23%), and cancer relapse in five cases (11%). The number of patients with intended curative treatment remained stable, while a considerable change in intended therapeutic intervention was noted after PET/CT, with an increase in planned chemotherapy from three to eleven patients and a decrease in planned surgical resection from eleven to two patients. In addition, PET/CT contributed to preventing patients from intended invasive procedures including biopsy and surgery in 8/43 (19%) cases and from additional diagnostic procedures in 25 (58%) cases. With the use of FDG-PET/CT as a tool to guide patient management in GCTs, we observed a notable impact on clinical staging and a consequent reduction in the need for additional invasive and diagnostic procedures. These findings are expected to be even more consequential in the future as treatment modalities improve and the life expectancy of GCT patients further increases. PET/CT considerably influences the clinical stage of GCT patients. PET/CT has remarkable influence on the choice of therapeutic interventions and reduces additional diagnostic procedures.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15143652